Soleus Capital Management, L.P. Adverum Biotechnologies, Inc. Transaction History

Soleus Capital Management, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.75 - $1.26 $318,750 - $535,500	425,000 New	425,000 $318,000
Q2 2023 Aug 14, 2023	BUY	$0.68 - $1.59 $217,600 - $508,800	320,000 New	320,000 $508,000
Q3 2022 Nov 14, 2022	BUY	$0.96 - $9.68 $5.36 Million - $54.1 Million	5,587,789 New	5,587,789 $5.31 Million
Q2 2021 Aug 16, 2021	SELL	$3.36 - $10.56 $335,973 - $1.06 Million	-99,992 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$9.26 - $14.36 $333,360 - $516,960	-36,000 Reduced 26.47%	99,992 $986,000
Q4 2020 Feb 16, 2021	SELL	$9.84 - $14.26 $2.25 Million - $3.26 Million	-228,357 Reduced 62.68%	135,992 $1.47 Million
Q3 2020 Nov 13, 2020	BUY	$10.3 - $21.64 $1.5 Million - $3.15 Million	145,626 Added 66.58%	364,349 $3.75 Million
Q2 2020 Aug 14, 2020	SELL	$8.53 - $25.64 $811,859 - $2.44 Million	-95,177 Reduced 30.32%	218,723 $4.57 Million
Q1 2020 May 15, 2020	SELL	$7.98 - $16.32 $230,622 - $471,648	-28,900 Reduced 8.43%	313,900 $3.07 Million
Q4 2019 Feb 14, 2020	BUY	$5.12 - $12.22 $1.76 Million - $4.19 Million	342,800 New	342,800 $3.95 Million

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Soleus Capital Management, L.P. with notifications on news.